First, PSMA expression is not entirely PCa-specific and high levels have been identified in the salivary glands, kidneys, nerve endings, and other sites of neoangiogenesis.19,20 This off-target expression is less problematic for imaging where low chemical and radiochemical doses are administered, but can cause severe, dose-limiting side-effects when using high-dose targeted radionuclide therapy. This evidence concerns the gene FOLH1 and posterior cortical atrophy.